New pill shows promise for psoriasis in early trial
NCT ID NCT06176768
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 35 times
Summary
This phase 2 trial tested an oral drug called LY3972406 in 33 adults with moderate-to-severe plaque psoriasis. The study compared the drug to a placebo to see if it could reduce skin symptoms. Results will help determine if larger studies are warranted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Accellacare - Winston-Salem
Winston-Salem, North Carolina, 27103, United States
-
Austin Institute for Clinical Research
Houston, Texas, 77056, United States
-
Center for Clinical Studies
Houston, Texas, 77004, United States
-
Clinical Science Institute
Santa Monica, California, 90404, United States
-
Conquest Research
Winter Park, Florida, 32789, United States
-
DermDox Centers for Dermatology
Camp Hill, Pennsylvania, 17011, United States
-
Dermatology Research Associates
Los Angeles, California, 90045, United States
-
Driven Research
Coral Gables, Florida, 33134, United States
-
Metropolitan Dermatology - Clark
Kenilworth, New Jersey, 07033, United States
-
Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey, 08520, United States
-
Remington-Davis, Inc
Columbus, Ohio, 43215, United States
-
Schweiger Dermatology Group
Hackensack, New Jersey, 07601, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY3972406 (oral drug)
What this could lead to
If successful, this could lead to a new oral treatment option for moderate-to-severe plaque psoriasis.
What could go wrong
This is a small, early-phase trial with only 33 participants. The drug may not prove effective or safe in larger studies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.